摘要目的 利用实时定量PCR方法检测急性白血病细胞系的NK配体表达,探讨不同来源白血病的NK配体差异表达规律.方法 通过实时定量PCR方法,以β-actin为内参基因,分别检测急性淋巴细胞白血病(ALL)细胞系(CEM、Jurkat T、Reh)和急性髓系白血病(AML)细胞系(HL-60、KG-1a、NB4)表面23种NK配体(MICA、MICB、ULBP-1、ULBP-2、ULBP-3、ULBP-4、HLA-E、HLA-G、CD48、NBTA、HLA-F、LLT-1、PVR、Nectin2、CD72、CD80、ICAM-1、LFA-3、CRACC、Fas、DR4、DR5、TNFR1)的表达情况,利用独立样本t检验进行组间比较.结果 有4种NK配体的表达水平在ALL组和AML组间差异具有统计学意义.其中,ULBP-2 ALL组(CEM细胞:1,Jurkat T细胞:0.617,Reh细胞:0.246)高于AML组(HL-60细胞:0.000,KG-1a细胞:0.003,NB4细胞:0.000)(P=0.047),CD48、PVR(PVR-1、PVR-2)和DR4 AML组(HL-60细胞分别为13.987、4.403、10.334、8.711,KG-1a细胞分别为5.387、2.900、7.315、4.512,NB4细胞分别为7.763、3.248、7.049、6.127)高于ALL组(CEM细胞均为1,Jurkat T细胞分别为2.035、1.553、3.888、0.449,Reh细胞分别为1.559、0.000、0.000、1.304)(P=0.044、0.014、0.014、0.011),而其余配体表达水平组间差异无统计学意义.结论 ULBP-2、CD48、PVR和DR4可能是ALL和AML的差异表达基因,为应用基于NK细胞的过继免疫治疗打下基础.

abstractsObjective To detect the expression profile of NK ligands in acute leukemia cell lines and investigate the differential expression pattern between acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Methods Using quantitative real-time PCR, 23 NK ligands (MICA, MICB, ULBP-1, ULBP-2, ULBP-3, ULBP-4, HLA-E, HLA-G, CD48, NBTA, HLA-F, LLT-1, PVR, Nectin2, CD72, CD80, ICAM-1, LFA-3, CRACC, Fas, DR4, DR5, TNFR1) were detected in 6 acute leukemia cell lines, including 3 ALL cell lines (CEM, Jurkat T, Reh) and 3 AML cell lines (HL-60, KG-1a, NB4), respectively. Independent-samples t test analysis was performed to determine statistical significance. Results Using β-actin as reference gene, the relative expression results showed that the expression of 4 NK ligands between ALL and AML is significantly different. Specifically, the level of ULBP-2 is higher in ALL (CEM: 1, Jurkat T: 0.617, Reh: 0.246) than that in AML (HL-60: 0.000, KG-1a: 0.003, NB4: 0.000)(P=0.047). However, the expressions of CD48, PVR(PVR-1, PVR-2) and DR4 is higher in AML (HL-60: 13.987, 4.403, 10.334, 8.711; KG-1a: 5.387, 2.900, 7.315, 4.512; NB4: 7.763, 3.248, 7.049, 6.127) than that in ALL (CEM: 1, 1, 1, 1; Jurkat T: 2.035, 1.553, 3.888, 0.449; Reh: 1.559, 0.000, 0.000, 1.304)(P=0.044, 0.014, 0.014, 0.011). And there're no significant differences between the rest 19 NK ligands. onclusions ULBP-2, CD48, PVR and DR4 might play an important role in the distinct mechanisms in leukemogenesis between ALL and AML and could be potential targets for diagnosis and treatment.